This compound is a pharmaceutical intermediate used in the synthesis of active pharmaceutical ingredients. It is a salt-like mixture containing an aromatic ring and carboxylic acid functional group, characterized by moderate polarity and lipophilicity.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Benzyl (3S,4S)-3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate
pharmaceutical intermediate
Benzyl (3R,4S)-3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate
pharmaceutical intermediate
Benzyl (3S,4R)-3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo-(2,3-e)pyrazin-8-yl)pyrrolidine-1-carboxylate
pharmaceutical intermediate
MK-1026 Intermediate-Biayrl Ether
pharmaceutical intermediate
4-[(Acetyloxy)methyl]-5-methyl-1,3-dioxol-2-one
pharmaceutical intermediate
4-(5,5-DIMETHYL-1,3,2-DIOXABORINAN-2-YL)-1H-PYRAZOLE
pharmaceutical intermediate
(3R,4S)-1-((Benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid
pharmaceutical intermediate
Sulfoxonium, (2-((3R,4S)-4-ethyl-1-((phenylmethoxy)carbonyl)-3-pyrrolidinyl)-2-oxoethyl)dimethyl-, inner salt, rel-
pharmaceutical intermediate
N-cyclohexylcyclohexanamine;4-ethyl-1-phenylmethoxycarbonylpyrrolidine-3-carboxylic acid
XQYOTLNAUVFWHH-UHFFFAOYSA-N
CCC1CN(CC1C(=O)O)C(=O)OCC2=CC=CC=C2.C1CCC(CC1)NC2CCCCC2
—
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.